Chronic obstructive pulmonary disease subpopulations and phenotyping

    loading  Checking for direct PDF access through Ovid

Abstract

INFORMATION FOR CATEGORY 1 CME CREDIT

Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions.

INFORMATION FOR CATEGORY 1 CME CREDIT

Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.jacionline.org. The accompanying tests may only be submitted online at www.jacionline.org. Fax or other copies will not be accepted.

INFORMATION FOR CATEGORY 1 CME CREDIT

Date of Original Release: June 2018. Credit may be obtained for these courses until May 31, 2019.

INFORMATION FOR CATEGORY 1 CME CREDIT

Copyright Statement: Copyright © 2018–2019. All rights reserved.

INFORMATION FOR CATEGORY 1 CME CREDIT

Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease.

INFORMATION FOR CATEGORY 1 CME CREDIT

Target Audience: Physicians and researchers within the field of allergic disease.

INFORMATION FOR CATEGORY 1 CME CREDIT

Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

INFORMATION FOR CATEGORY 1 CME CREDIT

List of Design Committee Members: Leopoldo N. Segal, MD, MS, and Fernando J. Martinez, MD, MS (authors); Zuhair K. Ballas, MD (editor)

INFORMATION FOR CATEGORY 1 CME CREDIT

Disclosure of Significant Relationships with Relevant Commercial

INFORMATION FOR CATEGORY 1 CME CREDIT

Companies/Organizations: L. N. Segal has received grants from the National Institutes of Health and personal fees from Advanced Inhalation Therapies. F. J. Martinez has received a grant from the National Heart, Lung, and Blood Institute; has received personal fees from Continuing Education, Forest Laboratories, GlaxoSmithKline, Nycomed/Takeda, AstraZeneca, Boehringer Ingelheim, Bellerophon (formerly Ikaria), Genentech, Novartis, Pearl, Roche, Sunovion, Theravance, CME Incite, the Annenberg Center for Health Sciences at Eisenhower, Integritas, InThought, the National Association for Continuing Education, Paradigm Medical Communications, PeerVoice, UpToDate, Haymarket Communications, the Western Society of Allergy and Immunology, Proterixbio, Unity Biotechnology, ConCert Pharmaceuticals, Lucid, Methodist Hospital, Columbia University, Prime Healthcare, WebMD, the PeerView Network, the California Society of Allergy and Immunology, Chiesi, and the Puerto Rico Thoracic Society and is on the COPD advisory board for Janssen. Z. K. Ballas (editor) disclosed no relevant financial relationships.

INFORMATION FOR CATEGORY 1 CME CREDIT

Activity Objectives:

INFORMATION FOR CATEGORY 1 CME CREDIT

Recognition of Commercial Support: This CME activity has not received external commercial support.

INFORMATION FOR CATEGORY 1 CME CREDIT

List of CME Exam Authors: Ryan Israelsen, MD, Katherine McCormack, MD, Hannah Duffey, MD, Allison Hicks, MD, Joseph Spahn, MD, and Maureen Egan, MD

INFORMATION FOR CATEGORY 1 CME CREDIT

Disclosure of Significant Relationships with Relevant Commercial

INFORMATION FOR CATEGORY 1 CME CREDIT

Companies/Organizations: The exam authors disclosed no relevant financial relationships.

INFORMATION FOR CATEGORY 1 CME CREDIT

The diagnosis and treatment of chronic obstructive pulmonary disease (COPD) has been based largely on a one-size-fits-all approach. Diagnosis of COPD is based on meeting the physiologic criteria of fixed obstruction in forced expiratory flows and treatment focus on symptomatic relief, with limited effect on overall prognosis. However, patients with COPD have distinct features that determine very different evolutions of the disease. In this review we highlight distinct subgroups of COPD characterized by unique pathophysiologic derangements, response to treatment, and disease progression. It is likely that identification of subgroups of COPD will lead to discovery of much needed disease-modifying therapeutic approaches. We argue that a precision approach that integrates multiple dimensions (clinical, physiologic, imaging, and endotyping) is needed to move the field forward in the treatment of this disease.

Related Topics

    loading  Loading Related Articles